R&G PharmaStudies Co. Ltd. A Asset Resilience Ratio
R&G PharmaStudies Co. Ltd. A asset resilience ratio. R&G PharmaStudies Co. Ltd. A (301333) has an Asset Resilience Ratio of 23.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301333 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of R&G PharmaStudies Co. Ltd. A (2023–2025)
Asset resilience ratio of R&G PharmaStudies Co. Ltd. A from 2023 to 2025. This chart shows how R&G PharmaStudies Co. Ltd. A's Asset Resilience Ratio has changed over time. Read 301333 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down R&G PharmaStudies Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 301333 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥574.90 Million | 23.94% |
| Total Liquid Assets | CN¥574.90 Million | 23.94% |
Asset Resilience Insights
- Good Liquidity Position: R&G PharmaStudies Co. Ltd. A maintains a healthy 23.94% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
R&G PharmaStudies Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare R&G PharmaStudies Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
R&G PharmaStudies Co. Ltd. A Asset Resilience Ratio by Year (2023–2025)
R&G PharmaStudies Co. Ltd. A asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for R&G PharmaStudies Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.84% | CN¥620.12 Million ≈ $90.74 Million |
CN¥2.40 Billion ≈ $351.14 Million |
-4.45pp |
| 2024-12-31 | 30.29% | CN¥707.61 Million ≈ $103.55 Million |
CN¥2.34 Billion ≈ $341.86 Million |
-4.06pp |
| 2023-12-31 | 34.35% | CN¥712.39 Million ≈ $104.24 Million |
CN¥2.07 Billion ≈ $303.46 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more